180 Life Sciences Corp. Director Stock Option Grant

On July 29, 2025, Stephen H. Shoemaker, a director of 180 Life Sciences Corp., was granted 919,761 non-qualified stock options under the 2025 Supplemental Option Plan. These options, which vest immediately, are not exercisable until the closing of the transactions contemplated by the July 29, 2025, Securities Purchase Agreement, which occurred on August 4, 2025. Additionally, the options are contingent upon stockholder approval of the 2025 Plan by July 29, 2026; otherwise, they will be cancelled. The exercise price for these options is $2.92, and they expire on July 29, 2035. Shoemaker also holds 132,439 shares of common stock in the company.